Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Jean Philippe Arnault, Christine Mateus, Bernard Escudier, Gorana Tomasic, Janine Wechsler, Emilie Hollville, Jean-Charles Soria, David Malka, Alain Sarasin, Magalie Larcher, Jocelyne André, Nyam Kamsu-Kom, Lise Boussemart, Ludovic Lacroix, Alain Spatz, Alexander M Eggermont, Sabine Druillennec, Stephan Vagner, Alain Eychène, Nicolas Dumaz, Caroline Robert
Clinical cancer research : an official journal of the American Association for Cancer Research 2012;18(1):263-72